• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Japan Clinical Trials Market

    ID: MRFR/HS/48505-HCR
    200 Pages
    Garvit Vyas
    September 2025

    Japan Clinical Trials Market Research Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Therapeutic Area (Oncology, Cardiology, Neurology, Infectious Diseases, Endocrinology) and By End Use (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Japan Clinical Trials Market Research Report — Global Forecast till 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    Japan Clinical Trials Market Summary

    The Japan Clinical Trials market is poised for substantial growth, projected to reach 3.6 USD Billion by 2035.

    Key Market Trends & Highlights

    Japan Clinical Trials Key Trends and Highlights

    • The market valuation for Japan Clinical Trials is estimated at 1.8 USD Billion in 2024.
    • From 2025 to 2035, the market is expected to grow at a CAGR of 6.5%.
    • By 2035, the market is anticipated to double in size, reaching 3.6 USD Billion.
    • Growing adoption of innovative technologies due to increasing demand for efficient drug development is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.8 (USD Billion)
    2035 Market Size 3.6 (USD Billion)
    CAGR (2025-2035) 6.5%

    Major Players

    Eisai, Ono Pharmaceutical, Gilead Sciences, Chugai Pharmaceutical, Roche, AbbVie, BristolMyers Squibb, Merck, Takeda Pharmaceutical, Astellas Pharma, Sanofi, Novartis, Pfizer, Johnson & Johnson, Mitsubishi Tanabe Pharma

    Japan Clinical Trials Market Trends

    The Japan Clinical Trials Market is seeing important changes as new innovative therapies are being created because the country is focusing on streamlining its clinical trial processes. One driver of the market is the growing partnerships between Japan's pharmaceutical firms and academic institutions.

    These partnerships seek to fast-track drug development while also ensuring that the processes are compliant with the tough standards of the PMDA. In addition, the growing elderly population in Japan is suffering from more chronic diseases, thereby increasing the demand for effective clinical trials to treat these challenges.

    The incorporation of advanced technologies like AI and big data into clinical trials has been recently noted. These technologies enhance recruitment and monitoring of patients, which leads to faster and more efficient processes. The Japanese government is also incentivizing the implementation of digital health technologies, which promotes automated decentralized clinical trials.

    This signifies a change in the way trials are conducted to meet the diverse requirements of the population. In addition, the focus on Japan’s “Accelerated Approval System” is aimed at creating novel pathways to deliver new drugs to the market more rapidly.

    This program motivates the creation of new therapies that tackle overlooked medical problems and is stimulating interest from foreign drug manufacturers that want to take advantage of the Japanese market. Japan's Clinical Trials Market as a whole demonstrates strong tendencies towards modernization, collaboration, and technological adoption in relation to the shifting population dynamics in the country.

    Japan Clinical Trials Market Drivers

    Market Segment Insights

    Get more detailed insights about Japan Clinical Trials Market Research Report — Global Forecast till 2035

    Regional Insights

    Key Players and Competitive Insights

    The Japan Clinical Trials Market is characterized by a dynamic landscape where various key players engage in robust competition. This market is driven by the rising need for innovative therapies and new drug development, along with an increasing emphasis on scientific research and technological advancements.

    The competitive environment is shaped by multiple factors, including regulatory frameworks, market access strategies, and collaborations between pharmaceutical companies and research institutions. The demand for efficient study protocols and patient recruitment processes has led organizations to refine their operational strategies and invest in cutting-edge technologies that can bolster their competitive edge.

    As a result, the market is not only evolving rapidly but is also witnessing an influx of biopharmaceutical entities attempting to secure their share while meeting the high standards set by both local and international regulatory bodies.

    Key Companies in the Japan Clinical Trials Market market include

    Industry Developments

    The Japan Clinical Trials Market has seen various recent developments and significant movements within key companies. Notably, in October 2023, Eisai announced the successful completion of Clinical Trials for its Alzheimer's disease drug, leading to a surge in investor interest.

    Moreover, Ono Pharmaceutical in September 2023 received Japanese regulatory approval for a new immunotherapy treatment, further enhancing its clinical portfolio. Also, Gilead Sciences is advancing its COVID-19 research in Japan, making strides in therapies for viral respiratory diseases.

    In terms of mergers and acquisitions, Takeda Pharmaceutical acquired a biotechnology firm focused on gene therapies in August 2023, strengthening its capabilities in innovative treatments. This acquisition reflects a broader trend of consolidation in the sector, driven by the need to expedite Research and Development processes and enhance therapeutic options.

    The market's growth trajectory is evident, with increased investments and collaborations, especially in oncology and rare diseases, propelled by companies like Chugai Pharmaceutical and Roche, which have been actively engaging in partnerships to optimize their clinical trial operations.

    The Japanese government continues to emphasize initiatives to streamline regulations and accelerate trial processes, fostering a conducive environment for innovation and growth in the market.

    Market Segmentation

    Clinical Trials Market Phase Outlook

    • Phase I
    • Phase II
    • Phase III
    • Phase IV

    Clinical Trials Market End Use Outlook

    • Pharmaceutical Companies
    • Biotechnology Companies
    • Contract Research Organizations

    Clinical Trials Market Study Design Outlook

    • Interventional
    • Observational
    • Expanded Access

    Clinical Trials Market Therapeutic Area Outlook

    • Oncology
    • Cardiology
    • Neurology
    • Infectious Diseases
    • Endocrinology

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 1.52(USD Billion)
    MARKET SIZE 2024 1.8(USD Billion)
    MARKET SIZE 2035 3.6(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 6.504% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Eisai, Ono Pharmaceutical, Gilead Sciences, Chugai Pharmaceutical, Roche, AbbVie, BristolMyers Squibb, Merck, Takeda Pharmaceutical, Astellas Pharma, Sanofi, Novartis, Pfizer, Johnson & Johnson, Mitsubishi Tanabe Pharma
    SEGMENTS COVERED Phase, Study Design, Therapeutic Area, End Use
    KEY MARKET OPPORTUNITIES Advancements in digital health technologies, Growing demand for personalized medicine, Increasing collaboration with global pharma, Strong support from regulatory authorities, Rising prevalence of chronic diseases
    KEY MARKET DYNAMICS Regulatory compliance challenges, Aging population driving demand, Advanced technology adoption, Increased R&D investments, Collaborations with global firms
    COUNTRIES COVERED Japan

    Market Highlights

    Author
    Garvit Vyas
    Analyst

    Explore the profile of Garvit Vyas, one of our esteemed authors at Market Research Future, and access their expert research contributions in the field of market research and industry analysis

    Leave a Comment

    FAQs

    What is the expected market size of the Japan Clinical Trials Market in 2024?

    The Japan Clinical Trials Market is expected to be valued at 1.8 billion USD in 2024.

    What will be the market size of the Japan Clinical Trials Market by 2035?

    By 2035, the Japan Clinical Trials Market is projected to reach a value of 3.6 billion USD.

    What is the anticipated CAGR for the Japan Clinical Trials Market from 2025 to 2035?

    The anticipated CAGR for the Japan Clinical Trials Market from 2025 to 2035 is 6.504%.

    Which phase of clinical trials will have the largest market share in 2024?

    Phase III is expected to hold the largest market share in 2024, valued at 0.72 billion USD.

    What is the projected value of Phase I clinical trials by 2035?

    The projected value of Phase I clinical trials is 0.72 billion USD by 2035.

    Who are the key players in the Japan Clinical Trials Market?

    Key players include Eisai, Ono Pharmaceutical, Gilead Sciences, and Takeda Pharmaceutical among others.

    How much is the Phase II segment of the Japan Clinical Trials Market expected to grow by 2035?

    The Phase II segment is expected to grow to 0.90 billion USD by 2035.

    What is the expected market size for Phase IV clinical trials in 2024?

    Phase IV clinical trials are expected to be valued at 0.27 billion USD in 2024.

    How do regional trends impact the Japan Clinical Trials Market?

    Regional trends significantly influence growth opportunities and resource allocation in the Japan Clinical Trials Market.

    What are the challenges facing the Japan Clinical Trials Market in the coming years?

    Challenges include regulatory hurdles, competition among key players, and evolving patient needs in the clinical trial landscape.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. Japan Clinical Trials Market, BY Phase (USD Billion)
    45. Phase I
    46. Phase II
    47. Phase III
    48. Phase IV
    49. Japan Clinical Trials Market, BY Study Design (USD Billion)
    50. Interventional
    51. Observational
    52. Expanded Access
    53. Japan Clinical Trials Market, BY Therapeutic Area (USD Billion)
    54. Oncology
    55. Cardiology
    56. Neurology
    57. Infectious Diseases
    58. Endocrinology
    59. Japan Clinical Trials Market, BY End Use (USD Billion)
    60. Pharmaceutical Companies
    61. Biotechnology Companies
    62. Contract Research Organizations
    63. Competitive Landscape
    64. Overview
    65. Competitive Analysis
    66. Market share Analysis
    67. Major Growth Strategy in the Clinical Trials Market
    68. Competitive Benchmarking
    69. Leading Players in Terms of Number of Developments in the Clinical Trials Market
    70. Key developments and growth strategies
    71. New Product Launch/Service Deployment
    72. Merger & Acquisitions
    73. Joint Ventures
    74. Major Players Financial Matrix
    75. Sales and Operating Income
    76. Major Players R&D Expenditure. 2023
    77. Company Profiles
    78. Eisai
    79. Financial Overview
    80. Products Offered
    81. Key Developments
    82. SWOT Analysis
    83. Key Strategies
    84. Ono Pharmaceutical
    85. Financial Overview
    86. Products Offered
    87. Key Developments
    88. SWOT Analysis
    89. Key Strategies
    90. Gilead Sciences
    91. Financial Overview
    92. Products Offered
    93. Key Developments
    94. SWOT Analysis
    95. Key Strategies
    96. Chugai Pharmaceutical
    97. Financial Overview
    98. Products Offered
    99. Key Developments
    100. SWOT Analysis
    101. Key Strategies
    102. Roche
    103. Financial Overview
    104. Products Offered
    105. Key Developments
    106. SWOT Analysis
    107. Key Strategies
    108. AbbVie
    109. Financial Overview
    110. Products Offered
    111. Key Developments
    112. SWOT Analysis
    113. Key Strategies
    114. BristolMyers Squibb
    115. Financial Overview
    116. Products Offered
    117. Key Developments
    118. SWOT Analysis
    119. Key Strategies
    120. Merck
    121. Financial Overview
    122. Products Offered
    123. Key Developments
    124. SWOT Analysis
    125. Key Strategies
    126. Takeda Pharmaceutical
    127. Financial Overview
    128. Products Offered
    129. Key Developments
    130. SWOT Analysis
    131. Key Strategies
    132. Astellas Pharma
    133. Financial Overview
    134. Products Offered
    135. Key Developments
    136. SWOT Analysis
    137. Key Strategies
    138. Sanofi
    139. Financial Overview
    140. Products Offered
    141. Key Developments
    142. SWOT Analysis
    143. Key Strategies
    144. Novartis
    145. Financial Overview
    146. Products Offered
    147. Key Developments
    148. SWOT Analysis
    149. Key Strategies
    150. Pfizer
    151. Financial Overview
    152. Products Offered
    153. Key Developments
    154. SWOT Analysis
    155. Key Strategies
    156. Johnson & Johnson
    157. Financial Overview
    158. Products Offered
    159. Key Developments
    160. SWOT Analysis
    161. Key Strategies
    162. Mitsubishi Tanabe Pharma
    163. Financial Overview
    164. Products Offered
    165. Key Developments
    166. SWOT Analysis
    167. Key Strategies
    168. References
    169. Related Reports
    170. Japan Clinical Trials Market SIZE ESTIMATES & FORECAST, BY PHASE, 2019-2035 (USD Billions)
    171. Japan Clinical Trials Market SIZE ESTIMATES & FORECAST, BY STUDY DESIGN, 2019-2035 (USD Billions)
    172. Japan Clinical Trials Market SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2035 (USD Billions)
    173. Japan Clinical Trials Market SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD Billions)
    174. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    175. ACQUISITION/PARTNERSHIP
    176. MARKET SYNOPSIS
    177. JAPAN CLINICAL TRIALS MARKET ANALYSIS BY PHASE
    178. JAPAN CLINICAL TRIALS MARKET ANALYSIS BY STUDY DESIGN
    179. JAPAN CLINICAL TRIALS MARKET ANALYSIS BY THERAPEUTIC AREA
    180. JAPAN CLINICAL TRIALS MARKET ANALYSIS BY END USE
    181. KEY BUYING CRITERIA OF CLINICAL TRIALS MARKET
    182. RESEARCH PROCESS OF MRFR
    183. DRO ANALYSIS OF CLINICAL TRIALS MARKET
    184. DRIVERS IMPACT ANALYSIS: CLINICAL TRIALS MARKET
    185. RESTRAINTS IMPACT ANALYSIS: CLINICAL TRIALS MARKET
    186. SUPPLY / VALUE CHAIN: CLINICAL TRIALS MARKET
    187. CLINICAL TRIALS MARKET, BY PHASE, 2025 (% SHARE)
    188. CLINICAL TRIALS MARKET, BY PHASE, 2019 TO 2035 (USD Billions)
    189. CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2025 (% SHARE)
    190. CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019 TO 2035 (USD Billions)
    191. CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2025 (% SHARE)
    192. CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2019 TO 2035 (USD Billions)
    193. CLINICAL TRIALS MARKET, BY END USE, 2025 (% SHARE)
    194. CLINICAL TRIALS MARKET, BY END USE, 2019 TO 2035 (USD Billions)
    195. BENCHMARKING OF MAJOR COMPETITORS

    Japan Clinical Trials Market Segmentation

     

     

     

    • Clinical Trials Market By Phase (USD Billion, 2019-2035)

      • Phase I
      • Phase II
      • Phase III
      • Phase IV

     

    • Clinical Trials Market By Study Design (USD Billion, 2019-2035)

      • Interventional
      • Observational
      • Expanded Access

     

    • Clinical Trials Market By Therapeutic Area (USD Billion, 2019-2035)

      • Oncology
      • Cardiology
      • Neurology
      • Infectious Diseases
      • Endocrinology

     

    • Clinical Trials Market By End Use (USD Billion, 2019-2035)

      • Pharmaceutical Companies
      • Biotechnology Companies
      • Contract Research Organizations

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials